Go to the list of all blogs
Jimmy Landsman's Avatar
published in Blogs
Nov 19, 2026
TickeronGET DAILY SIGNALS
XMAR: First Trust’s Defined Outcome ETF Targets Enhanced SPY Returns With a 15% Buffer

XMAR: First Trust’s Defined Outcome ETF Targets Enhanced SPY Returns With a 15% Buffer

Key Takeaways

  • XMAR is an actively managed exchange-traded fund (ETF) from First Trust and sub-advisor Vest Financial LLC, launched in March 2023.
  • It belongs to the "defined outcome" or "buffered ETF" category, using options to seek enhanced upside and a degree of downside protection over a one-year period.
  • The fund's objective is to pursue roughly twice the positive price return of the SPDR S&P 500 ETF Trust, up to a predetermined cap, while buffering against the first 15% of losses.
  • XMAR carries a net expense ratio of 0.85% and is non-diversified, holding primarily flexible exchange (FLEX) options tied to the S&P 500.
  • The ETF is designed for investors seeking equity exposure with defined risk parameters rather than unconstrained index returns.

Getting to Know XMAR

The FT Vest U.S. Equity Enhance & Moderate Buffer ETF - March, trading under the ticker XMAR, is a specialized exchange-traded fund (ETF) that offers a structured approach to U.S. large-cap equity investing. An ETF is a pooled investment vehicle that trades on an exchange like a stock and holds a basket of assets. Rather than simply tracking the S&P 500, XMAR uses an options-based strategy to seek amplified upside up to a cap, together with a built-in buffer against a portion of potential losses. This "defined outcome" approach has attracted attention from investors who want market participation while seeking to manage downside risk over a specific holding period. I also checked comparable products using Tickeron’s AI Screener to see how the structure stacks up against other buffered strategies.

The Fund’s Structure and Objectives

XMAR is issued by First Trust, with Vest Financial LLC serving as portfolio sub-advisor. The fund was launched on March 17, 2023, and its shares trade on the Cboe BZX exchange. It is categorized by Morningstar under the "Defined Outcome" group, a family of products sometimes called buffered ETFs or target-outcome ETFs.

The fund's investment objective is to provide returns, before fees and expenses, of approximately twice any positive price return of the SPDR S&P 500 ETF Trust (ticker SPY), up to a predetermined upside cap, while offering a buffer against the first 15% of the underlying ETF's losses. These parameters are reset each year for a target outcome period that generally runs from one March to the next.

To achieve this, XMAR is actively managed and invests substantially all of its assets in FLexible EXchange (FLEX) options that reference the price performance of SPY. Because the fund is built from options contracts rather than a broad basket of individual stocks, its portfolio holdings are concentrated: the fund typically reports only a handful of positions, consisting of options on SPY plus cash or money-market instruments used as collateral.

Although XMAR does not directly hold a diversified list of stocks, its economic exposure broadly mirrors the S&P 500 through the underlying ETF. As a result, its indirect sector exposure has historically leaned heavily toward technology, followed by financial services, communication services, consumer cyclical, and healthcare. The fund is non-diversified, meaning it is not required to meet the same diversification thresholds as a typical registered investment company. From what I see, this concentration is typical for options-based defined outcome products.

XMAR's net expense ratio is 0.85%, which is higher than a plain index-tracking S&P 500 fund but is typical for a structured, options-based product that must actively manage and roll derivatives positions. The fund does not generally distribute dividends, and its total net assets have been in the range of roughly $150 million to $160 million.

What Draws Investors to This Approach

XMAR attracts interest from investors who want U.S. equity exposure but prefer a defined trade-off between upside and downside. Its "enhance and buffer" design means that, during a favorable year, the fund aims to deliver approximately double the underlying ETF's positive price return, though only up to a stated cap. Conversely, during a down year, the buffer is designed to absorb the first 15% of losses before the investor bears further declines.

This structured profile can serve as a building block for portfolios seeking to reduce the emotional and financial impact of equity drawdowns. It is especially relevant in environments of elevated market volatility, where the combination of capped upside and partial downside protection may appeal to conservative or income-oriented investors looking for a more predictable range of outcomes over a known holding period. The strategy's one-year reset also gives investors a recurring, clearly defined window for evaluating results. One thing that stands out is how the annual reset creates a clear evaluation cycle each March.

Key Risks to Consider

Investors should understand several important limitations before considering XMAR. The upside cap means the fund will not fully participate in strong market rallies; gains beyond the cap are forfeited for that outcome period. If shares are purchased after the start of a target outcome period, the investor's effective upside and downside parameters may differ from those advertised at launch, and in some cases there may be little or no remaining upside.

The buffer is not a guarantee: losses beyond the first 15% are borne fully by the investor. Because the cap and buffer reset each year, an investor who holds through multiple outcome periods may not recoup prior losses the way an unconstrained index investor might. XMAR is also non-diversified and concentrated in options, exposing it to counterparty risk, the risk of pricing and liquidity in derivatives markets, and potential tracking differences relative to the underlying ETF. Its 0.85% expense ratio is materially higher than a standard S&P 500 index fund, which can erode returns over time. Investors who buy or sell shares between outcome periods may also experience results that differ substantially from the fund's stated target.

Researching Structured ETFs With AI Tools

When evaluating options-based funds like XMAR, I often turn to Tickeron’s AI Screener to quickly compare parameters across similar defined outcome ETFs. The platform helps surface ideas based on volatility, sector exposure, and outcome period details, which can be useful for aligning a position with a broader portfolio plan. In my view, it streamlines the process of reviewing how different caps and buffers stack up without manually sorting through dozens of prospectuses.

Conclusion

The FT Vest U.S. Equity Enhance & Moderate Buffer ETF - March (XMAR) stands out for its defined-outcome design, which trades unlimited upside for a structured combination of enhanced returns and partial downside protection over a one-year window. Its options-based approach makes it more complex than a traditional index ETF, and its cap, buffer, and expense ratio require careful consideration. For investors who value predictable risk parameters and are comfortable with the trade-offs involved, XMAR remains a noteworthy example of how ETFs can be engineered to deliver tailored market exposure.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: XMAR

Contributor

My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.


Momentum Indicator for XMAR turns negative, indicating new downward trend

XMAR saw its Momentum Indicator move below the 0 level on November 16, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator turned negative. In 11 of the 38 cases, the stock moved further down in the following days. The odds of a decline are at 29%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for XMAR turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 36 similar instances when the indicator turned negative. In 10 of the 36 cases the stock turned lower in the days that followed. This puts the odds of success at 28%.

XMAR moved below its 50-day moving average on November 16, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XMAR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 19%.

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Following a +0.91% 3-day Advance, the price is estimated to grow further. Considering data from situations where XMAR advanced for three days, in 149 of 322 cases, the price rose further within the following month. The odds of a continued upward trend are 46%.

XMAR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 226 of 456 cases where XMAR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 50%.

Industry description

The investment seeks to provide investors with returns of approximately twice any positive price return of the State Street® SPDR® S&P 500® ETF Trust (the “Underlying ETF”), up to a predetermined upside cap of 12.22% while providing a buffer against the first 15% of Underlying ETF losses, over the period from March 23, 2026 through March 19, 2027. Under normal market conditions, the fund will invest substantially all of its assets in FLexible EXchange ® Options that reference the price performance of the SPDR ® S&P 500 ® ETF Trust. The fund is non-diversified.
Real Time Patterns 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.
Cerebras Systems (CBRS) dropped -6.48% to $97.43 in regular trading from the prior close of $104.18, reversing an early premarket gain of roughly +3%. No verified news or fundamental catalyst found for the intraday reversal; the move is likely profit-taking after the stock's +21% post-earnings rebound, consistent with a name that averages a ±4.5% daily swing and remains 65% below its first-day close.
CBRS fell -6.07% to $97.86 in the opening minutes of Wednesday's regular session, down from Tuesday's close of $104.18 — the move occurred during market hours, not premarket or after-hours. No verified news or fundamental catalyst found: no new filing, contract, or analyst action explains the drop, which is likely continued give-back from the post-earnings pop and the stock's habitual volatility — CBRS has averaged a ±4.5% daily swing over the past 60 sessions, and 17 of those sessions moved as much or more.